Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Starting soon Not applicable

Teach-Back Discharge Education After Pilonidal Sinus Surgery

NCT07851285 · tracked via the Priya Life Science Turkey tracker
Phase
Not applicable
Started
2026-09-15
Last updated
2026-10-01

Condition(s) studied

Pilonidal Sinus DiseasePilonidal Sinus Treatment

Investigational drug(s) / intervention(s)

Teach-Back-Supported Discharge EducationRoutine Discharge Education

Teach-Back-Supported Discharge Education: Participants will receive individualized discharge education using the Teach-Back method. The education will cover wound care, personal hygiene, pain management, sitting and mobility, activities of daily living, bowel elimination, signs of complications, and situations requiring medical consultation. Participants will be asked to explain the information in their own words. Any misunderstood or incomplete information will be clarified and reassessed until correct understanding is demonstrated.

Routine Discharge Education: Participants will receive the hospital's routine discharge education and standard postoperative care. No additional education using the Teach-Back method will be provided by the researchers.

Study summary

This randomized controlled trial will evaluate the effect of Teach-Back-supported discharge education on self-care agency, pain intensity, and comfort levels in patients undergoing surgery for pilonidal sinus disease. A total of 68 participants will be randomly assigned in a 1:1 ratio to either the intervention group or the control group. The intervention group will receive discharge education using the Teach-Back method, while the control group will receive routine discharge education and standard care. Self-care agency, pain intensity, and comfort levels will be assessed at baseline and on the tenth day after discharge.

Eligibility

Sex
ALL
Min age
18 Years
Max age
65 Years
Healthy volunteers
No
Inclusion Criteria: * Being between 18 and 64 years of age Having undergone elective surgery for pilonidal sinus disease Being clinically stable after surgery Being able to read and understand Turkish and communicate verbally in Turkish Having no cognitive, hearing, or visual impairment severe enough to prevent participation in the education process or completion of the data collection forms Being scheduled to attend the follow-up visit on the tenth day after discharge Volunteering to participate in the study and providing written informed consent Exclusion Criteria: Being 65 years of age or older Having undergone emergency surgery for pilonidal sinus disease Having undergone another surgical procedure during the same operative session in addition to pilonidal sinus surgery Having previously undergone pilonidal sinus surgery and being reoperated on because of recurrence Requiring postoperative intensive care or being clinically unsuitable to participate in the education Having a diagnosed severe cognitive disorder, psychiatric disorder, or neurological condition that prevents effective communication Being unable to communicate in Turkish Having a physical or cognitive impairment that prevents independent management of self-care and the discharge process Being unable to complete the scales or data collection forms used in the study \-

Primary outcome measure(s)

  • Change in Self-Care Agency Score — Baseline and 10 days after discharge
    Self-care agency will be assessed using the Exercise of Self-Care Agency Scale. The scale consists of 35 items scored from 0 to 4, with a total score ranging from 0 to 140. Higher scores indicate greater self-care agency. The change in scores from baseline to the tenth day after discharge will be compared between the intervention and control groups.
  • Change in General Comfort Score — Baseline and 10 days after discharge
    General comfort will be assessed using the General Comfort Questionnaire. The questionnaire consists of 48 items evaluating physical, psychospiritual, sociocultural, and environmental dimensions of comfort. Higher scores indicate a higher level of comfort. The change in scores from baseline to the tenth day after discharge will be compared between the intervention and control groups.

Trial sites (1)

FacilityCityRegionStatus
Istanbul Buyukcekmece Mimar Sinan State Hospital Istanbul Turkey (Türkiye)
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07851285 on ClinicalTrials.gov ↗ ← All trials in Turkey